Combination therapy with miR34a and doxorubicin synergistically inhibits Dox-resistant breast cancer progression
10.1016/j.apsb.2021.06.003
- Author:
Xiaoxia YANG
1
;
Pengfei SHANG
1
;
Bingfang YU
1
;
Qiuyang JIN
1
;
Jing LIAO
1
;
Lei WANG
1
;
Jianbo JI
1
;
Xiuli GUO
1
Author Information
1. Department of Pharmacology, Key Laboratory of Chemical Biology (Ministry of Education), Drug Screening Unit Platform, School of Pharmaceutical Sciences, Shandong University, Jinan 250012, China.
- Publication Type:Journal Article
- Keywords:
Breast cancer;
Dox;
Drug resistance;
Notch/NF-κB;
RAS/RAF/MEK/ERK;
Snail;
Therapy;
miR34a
- From:
Acta Pharmaceutica Sinica B
2021;11(9):2819-2834
- CountryChina
- Language:English
-
Abstract:
Resistance to breast cancer (BCa) chemotherapy severely hampers the patient's prognosis. MicroRNAs provide a potential therapeutic prospect for BCa. In this study, the reversal function of microRNA34a (miR34a) on doxorubicin (Dox) resistance of BCa and the possible mechanism was investigated. We found that the relative level of miR34a was significantly decreased in Dox-resistant breast cancer cell MCF-7 (MCF-7/A) compared with Dox-sensitive MCF-7 cells. Transfection with miR34a significantly suppressed the invasion, migration, adhesion of MCF-7/A cells without inhibiting their growth obviously. The combination of miR34a and Dox could significantly inhibit the proliferation, migration, invasion and induce the apoptosis of MCF-7/A cells. The synergistic effect of this combination on resistant MCF-7/A cells has no obvious relation with the expressions of classical drug-resistant proteins P-GP, MRP and GST-
